Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03426826 · ClinicalTrials.gov registry record · Phase 1

The Gut-Brain Study

A Phase 1 study of Autism Spectrum Disorder (ASD) and Gastro-Intestinal Disorder, sponsored by Children's Hospital Los Angeles.

Active
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT03426826 is a Phase 1 study of Autism Spectrum Disorder (ASD) and Gastro-Intestinal Disorder that is active but no longer recruiting, run by Children's Hospital Los Angeles. The registered enrollment target is 10 participants, below the 102-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03426826, a Phase 1 study of Autism Spectrum Disorder (ASD) and Gastro-Intestinal Disorder, is active but no longer recruiting, sponsored by Children's Hospital Los Angeles.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if transplant of fecal matter (stool), also known as fecal microbiota transplantation (FMT), from a healthy person into the intestines of children and young adults with Autism Spectrum Disorder (ASD). For this study children between the ages of 5-17years will be recruited over 2 years. Children will be recruited who receive an ASD diagnosis using the gold-standard Autism Diagnosis Observation Schedule -2 (ADOS-2) using module 1, 2 or 3 (none, limited or no moderate expressive language). Children diagnosed with these modules of the ADOS-2 may be at greater risk for GI disorders and rigid-compulsive behaviors. Additional assessment of rigid-compulsive behaviors and social communication will be done using the Repetitive Behavioral Scales-Revised (RBS-R) and Social Responsiveness Scale-2 (SRS-2), respectively. KBIT (the Kaufman Brief Intelligence Test) is used at baseline to obtain patient IQ. Total evaluation time is approximately 90 minutes. Following baseline symptom evaluation, a medical exam will be performed to determine whether each child is expressing specific GI symptoms. In addition, parents will fill out the Questionnaire for Pediatric Gastrointestinal Symptoms- Rome III (QPGS-III). Once an ASD diagnosis is confirmed, FMT treatment will be initiated, which typically occurs within 4-6 weeks of the initial diagnosis. Half 50% of the children (n=5) will receive the equivalent of 50 g of stools from a healthy donor into the jejunum through upper endoscopy and the other 50% off children (n=5) will receive Saline solution as Placebo control through upper endoscopy. Subjects will have a total of 5 visits within 24 weeks including phone call follow up on Day 7 after FMT.

Interventions

  • BIOLOGICAL FMT versus placebo

Study Locations (1)

California

  • Children's Hospital Los Angles - Los Angeles

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-08-15
Est. Completion 2026-06
Phase Phase 1

Sponsor

Children's Hospital Los Angeles

119 total trials

What the Registry Record Tells You About NCT03426826

The ClinicalTrials.gov registry entry for NCT03426826 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (90% lower). The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Autism Spectrum Disorder (ASD) appearing as the primary indexed condition, and to 1 intervention - of which FMT versus placebo is the first listed.

NCT03426826 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03426826 about?

NCT03426826 is a clinical study titled "The Gut-Brain Study". The purpose of this study is to find out if transplant of fecal matter (stool), also known as fecal microbiota transplantation (FMT), from a healthy person into the intestines of children and young adults with Autism Spectrum Disorder (ASD). For this study children between the ages of 5-17years wil...

What is the current status of trial NCT03426826?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-08-15. Estimated completion is 2026-06.

What conditions does trial NCT03426826 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder (ASD), Gastro-Intestinal Disorder.

What interventions are being tested in trial NCT03426826?

The interventions under investigation include: FMT versus placebo (BIOLOGICAL).

Who is sponsoring clinical trial NCT03426826?

This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03426826 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder (ASD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.